Literature DB >> 11815691

Olanzapine usage associated with neuroleptic malignant syndrome.

R A Philibert1, L A Adam, F M Frank, C Carney-Doebbeling.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11815691     DOI： 10.1176/appi.psy.42.6.528

Source DB:  PubMed          Journal:  Psychosomatics        ISSN： 0033-3182            Impact factor:   2.386


× No keyword cloud information.
  3 in total

Review 1.  Children with schizophrenia: clinical picture and pharmacological treatment.

Authors:  Gabriele Masi; Maria Mucci; Cinzia Pari
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 2.  Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.

Authors:  Paz Toren; Sharon Ratner; Nathaniel Laor; Abraham Weizman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

3.  Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine.

Authors:  Enasio Morris; Digby Green; Andis Graudins
Journal:  J Med Toxicol       Date:  2009-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.